Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.41 |
| ▸ | DPP4 known ✓ | P27487 | 4/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3862327 | 1.00 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL133898 | 1.00 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL135153 | 1.00 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL1938939 | 1.00 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL475806 | 1.00 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL833267 | 1.00 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL6200345 | 1.00 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL589711 | 0.98 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1303905 | 0.98 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3542501 | 0.98 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017529-A1 | NOVEL L-PROLINE SULFONAMIDE DERIVATIVES COMPRISING PYRAZOLO[4,3- E]TETRAZOLO[4,5-B][1,2,4]TRIAZINE SYSTEM, METHOD OF MANUFACTURING THEREOF, USES THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | UNIWERSYTET MEDYCZNY W LUBLINIE (PL) | 2022-01-20 | — | — | US | claimed |
| EP-3886990-A1 | NOVEL L-PROLINE SULFONAMIDE DERIVATIVES COMPRISING PYRAZOLO[4,3- E]TETRAZOLO[4,5-B][1,2,4]TRIAZINE SYSTEM, METHOD OF MANUFACTURING THEREOF, USES THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Uniwersytet Medyczny W Bialymstoku (PL) | 2021-10-06 | — | — | EP | claimed |
| WO-2020111956-A1 | NOVEL L-PROLINE SULFONAMIDE DERIVATIVES COMPRISING PYRAZOLO[4,3- E]TETRAZOLO[4,5-B][1,2,4]TRIAZINE SYSTEM, METHOD OF MANUFACTURING THEREOF, USES THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | UNIWERSYTET MEDYCZNY W BIAŁYMSTOKU (PL) | 2020-06-04 | — | — | WO | claimed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250230154-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-07-17 | — | — | US | disclosed |
| US-20250228944-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-20250145608-A1 | KRAS DEGRADING COMPOUNDS COMPRISING ANNULATED 2-AMINO-3-CYANO THIOPHENES | BOEHRINGER INGELHEIM INTL GMBH CORP (DE) | 2025-05-08 | — | — | US | disclosed |
| US-12275716-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| CN-109251211-B | Quinolone carboxylic acid compound and intermediate thereof, preparation method and application | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2025-03-07 | — | — | CN | disclosed |
| US-12171831-B2 | Compounds and methods for the targeted degradation of bromodomain- containing proteins | ARVINAS OPERATIONS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240252653-A1 | CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2024-08-01 | — | — | US | disclosed |
| EP-1263773-A1 | OLIGONUCLEOTIDE ANALOGUES, METHODS OF SYNTHESIS AND METHODS OF USE | Active Motif (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020155989-A1 | Oligonucleotide analogues, methods of synthesis and methods of use | ACTIVE MOTIF | 2002-10-24 | — | — | US | disclosed |
| US-6316626-B1 | Amine compounds and combinatorial libraries comprising same | ISIS PHARMACEUTICALS, INC. | 2001-11-13 | — | — | US | disclosed |
| WO-2001068673-A1 | OLIGONUCLEOTIDE ANALOGUES, METHODS OF SYNTHESIS AND METHODS OF USE | ACTIVE MOTIF (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-1999012034-A1 | AMINE COMPOUNDS AND COMBINATORIAL LIBRARIES COMPRISING SAME | ISIS PHARMACEUTICALS, INC. (US) | 1999-03-11 | — | — | WO | disclosed |
| US-5447925-A | Carbapenems with side-chain S; use to treat infections | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-09-05 | — | — | US | disclosed |
| US-5409946-A | Antiepileptic agent | ABBOTT LABORATORIES (US) | 1995-04-25 | — | — | US | disclosed |
| EP-0580632-A1 | ANTIBIOTIC CARBAPENEM DERIVATIVES | ZENECA LIMITED (GB) | 1994-02-02 | — | — | EP | disclosed |
| WO-1992017480-A1 | ANTIBIOTIC CARBAPENEM DERIVATIVES | ZENECA LTD. (GB) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017529-A1 | NOVEL L-PROLINE SULFONAMIDE DERIVATIVES COMPRISING PYRAZOLO[4,3- E]TETRAZOLO[4,5-B][1,2,4]TRIAZINE SYSTEM, METHOD OF MANUFACTURING THEREOF, USES THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | PGA5, APC, API5 | CHRNB4 4879/4885CHRNA3 4881/4885CHRNA7 4882/4885 |
| US-20250230154-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | PTPN1, PTPN5, PTPN2 | CHRNB4 4802/4885CHRNA3 4839/4885CHRNA7 4806/4885 |
| US-20020155989-A1 | Oligonucleotide analogues, methods of synthesis and methods of use | HIRA, PHAX, SSU72 | CHRNB4 1352/4885CHRNA3 639/4885CHRNA7 818/4885 |
| US-12275716-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | CHRNB4 990/4885CHRNA3 1657/4885CHRNA7 2318/4885 |
| US-20250145608-A1 | KRAS DEGRADING COMPOUNDS COMPRISING ANNULATED 2-AMINO-3-CYANO THIOPHENES | KRAS, NRAS, TP53 | CHRNB4 4850/4885CHRNA3 4871/4885CHRNA7 4883/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | CHRNB4 1493/4885CHRNA3 1155/4885CHRNA7 1211/4885 |
| US-12171831-B2 | Compounds and methods for the targeted degradation of bromodomain- containing proteins | BRPF3, STUB1, BRDT | CHRNB4 4022/4885CHRNA3 4113/4885CHRNA7 4490/4885 |
| US-20240252653-A1 | CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION | RNASE1, IGF2BP1, IGF2BP2 | CHRNB4 3167/4885CHRNA3 2505/4885CHRNA7 2542/4885 |
| US-20250228944-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | CHRNB4 4022/4885CHRNA3 4113/4885CHRNA7 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.